Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

This study is testing a new drug called MT-302 in adults with advanced or metastatic cancer (cancer that has spread or cannot be surgically removed). MT-302 is an experimental treatment being evaluated in a range of cancer types that have not responded to standard therapies. The study is primarily a Phase 1 trial, meaning it is focused on safety and finding the right dose. **You may be eligible if...** - You are 18 years or older - You have advanced or metastatic cancer of one of the following types: bladder, cervical, ovarian, triple-negative breast, hormone receptor-positive breast, pancreatic, stomach, esophageal, non-small cell lung, or colorectal cancer - Your cancer has progressed on or after standard treatments, or you have declined standard treatment - You are physically well enough to carry out normal daily activities (ECOG 0–1) - Your heart and organ function meets the required minimums - You have a life expectancy of more than 12 weeks **You may NOT be eligible if...** - Your cancer is not one of the listed types - You have significant heart problems or abnormal heart electrical activity - Your oxygen levels are below 90% on room air - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.